Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 13/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vimseltinib SCHEMBL30453793 | 1.00 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| Vimseltinib SCHEMBL31615255 | 0.99 | CSF1R (0.98) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31741098 | 0.90 | CSF1R (0.82) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046817 | 0.89 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909908 | 0.89 | CSF1R (0.79) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046264 | 0.88 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31741155 | 0.88 | CSF1R (0.78) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909923 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16048025 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909802 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260142007-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | REMEPY HEALTH LTD (IL) | 2026-05-21 | — | — | US | claimed |
| US-20260028587-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | NOVOGLIA, INC. | 2026-01-29 | — | — | US | claimed |
| US-20260000652-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2026-01-01 | — | — | US | claimed |
| EP-4551209-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119799717-A | Preparation combination and application of nucleic acid form IL-9 combined immune checkpoint drug | 诺未生物技术(无锡)有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025065747-A1 | APPLICATION OF CSF1R INHIBITOR IN PREPARATION OF NK/T CELL LYMPHOMA TREATMENT DRUG | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-03 | — | — | WO | claimed |
| EP-4346669-A1 | DEVICES, METHODS, AND COMPOSITIONS FOR THERMAL ACCELERATION AND DRUG DELIVERY | Theromics, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117624132-A | Preparation method of CSF-1R kinase inhibitor Vimseltinib (DCC-3014) | 上海相辉医药科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117642130-A | Devices, methods and compositions for thermal acceleration and drug delivery | 塞罗米斯有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117427166-A | Application of CSF1R inhibitor in preparation of NK/T cell lymphoma therapeutic drug | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2024-01-23 | — | — | CN | claimed |
| EP-3902547-A1 | CSF1R INHIBITORS FOR USE IN TREATING CANCER | Deciphera Pharmaceuticals, LLC (US) | 2021-11-03 | — | — | EP | claimed |
| CN-113453684-A | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2021-09-28 | — | — | CN | claimed |
| US-20200253973-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2020-08-13 | — | — | US | claimed |
| WO-2020139828-A1 | CSF1R INHIBITORS FOR USE IN TREATING CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-07-02 | — | — | WO | claimed |
| CN-107311981-B | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity | 德西费拉制药有限责任公司 | 2020-05-29 | — | — | CN | claimed |
| EP-2968286-B1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-09-13 | — | — | EP | claimed |
| EP-2968286-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | claimed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | claimed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253973-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, CD68 | CSF1R 1/4885PDGFRA 299/4885PDGFRB 168/4885 |
| US-20260000652-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | CSF1R, CSF3R, MCL1 | CSF1R 1/4885PDGFRA 427/4885PDGFRB 87/4885 |
| US-20260028587-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | CSF1R, CSF3R, GMFG | CSF1R 1/4885PDGFRA 252/4885PDGFRB 108/4885 |
| US-20260142007-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | CSF1R, CSF3R, CXCL12 | CSF1R 1/4885PDGFRA 68/4885PDGFRB 46/4885 |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 6/4885PDGFRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.